Physics simulations took weeks to screen libraries. Boltz-2 runs 1,000x faster, cutting this to hours with 2x precision.
A clinical-stage biotechnology company manages 50 petabytes of biological and chemical data to industrialize the drug discovery process.
Traditional physics-based simulations required weeks to screen compound libraries, while earlier AI models could not accurately predict how strongly...
AI-driven drug discovery and clinical-stage biotechnology platform.
MIT researchers co-developed the Boltz-2 biomolecular foundation model with Recursion.
NVIDIA is a technology company that specializes in semiconductors, graphics processing units, and artificial intelligence for applications in data centers, gaming, and more.
Recursion's Drug discovery is part of this use case:
Related implementations across industries and use cases
Matching phages required screening trillions of options. Gen AI simulates interactions, cutting discovery from 10 years to 2 months.
Mapping interactions took years. A custom AI pipeline analyzed 1.7M predictions in 3 months, finding 40,000 high-confidence pairs.
Navigating 10^1000 variants was impossible. A model designed novel proteins, boosting stem cell marker expression >50x over controls.
Matching phages required screening trillions of options. Gen AI simulates interactions, cutting discovery from 10 years to 2 months.
Mapping interactions took years. A custom AI pipeline analyzed 1.7M predictions in 3 months, finding 40,000 high-confidence pairs.
Insurance bottlenecks delayed critical therapies for months. Now, AI verifies coverage, freeing care teams to guide patients to treatment.
Manual scheduling trapped recruiters in logistics. AI now automates interview coordination, freeing teams for strategic work.
Protecting users from harmful on-device AI required internet. A powerful safety AI now runs directly on the PC, guarding users even when offline.
A 200% yearly data expansion bottlenecked global operations. Now, AI accelerates coding, drafts recipe cards, and resolves inquiries.
Physics simulations took weeks to screen libraries. Boltz-2 runs 1,000x faster, cutting this to hours with 2x precision.
A clinical-stage biotechnology company manages 50 petabytes of biological and chemical data to industrialize the drug discovery process.
Traditional physics-based simulations required weeks to screen compound libraries, while earlier AI models could not accurately predict how strongly...
AI-driven drug discovery and clinical-stage biotechnology platform.
MIT researchers co-developed the Boltz-2 biomolecular foundation model with Recursion.
NVIDIA is a technology company that specializes in semiconductors, graphics processing units, and artificial intelligence for applications in data centers, gaming, and more.
Recursion's Drug discovery is part of this use case:
Related implementations across industries and use cases
Matching phages required screening trillions of options. Gen AI simulates interactions, cutting discovery from 10 years to 2 months.
Mapping interactions took years. A custom AI pipeline analyzed 1.7M predictions in 3 months, finding 40,000 high-confidence pairs.
Navigating 10^1000 variants was impossible. A model designed novel proteins, boosting stem cell marker expression >50x over controls.
Matching phages required screening trillions of options. Gen AI simulates interactions, cutting discovery from 10 years to 2 months.
Mapping interactions took years. A custom AI pipeline analyzed 1.7M predictions in 3 months, finding 40,000 high-confidence pairs.
Insurance bottlenecks delayed critical therapies for months. Now, AI verifies coverage, freeing care teams to guide patients to treatment.
Manual scheduling trapped recruiters in logistics. AI now automates interview coordination, freeing teams for strategic work.
Protecting users from harmful on-device AI required internet. A powerful safety AI now runs directly on the PC, guarding users even when offline.
A 200% yearly data expansion bottlenecked global operations. Now, AI accelerates coding, drafts recipe cards, and resolves inquiries.